News

Industry News

View All » Industry News RSS Feed
Ranitidine Hydrochloride Recall Expanded to Other Companies

Ranitidine Hydrochloride Recall Expanded to Other Companies

After Sandoz Inc. voluntarily recalled all quantities and lots within expiry of ranitidine hydrochloride due to confirmed contamination of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, three other major companies are recalling ranitidine hydrochloride as well for the same issue.

Read More »
Reyvow (Lasmiditan) Tablets Approved for Acute Migraine

Reyvow (Lasmiditan) Tablets Approved for Acute Migraine

The FDA has approved Reyvow (lasmiditan) tablets for the acute treatment of migraine with or without aura in adults. This drug is not indicated for the preventive treatment of migraine and can cause driving impairment, which is why Reyvow is pending controlled substance scheduling.

Read More »